文献速递间质性肺疾病

吡非尼酮对特发性肺纤维化患者呼吸困难的影响

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis.
PubMed 文献 · Eur Respir J · 2019-09-30

该研究为IPF临床试验的事后分析,旨在进一步评估吡非尼酮对比安慰剂对呼吸困难严重程度的影响,包括12个月内呼吸困难较基线的变化及12个月时呼吸困难的分类变化。分析提示,在疾病更晚期(GAP II/III期或FVC<80%)的患者中,吡非尼酮可能延缓患者报告的呼吸困难恶化。

要点

  • 吡非尼酮可能延缓疾病更晚期IPF患者呼吸困难的恶化。
  • 获益人群为GAP II/III期或FVC<80%的患者。
  • 呼吸困难是影响IPF患者健康相关生活质量的重要因素。

核心结论

  • 在疾病更晚期(GAP II/III期或FVC<80%)的IPF患者中,吡非尼酮对比安慰剂可能延缓12个月内患者报告的呼吸困难恶化。

研究设计与样本

  • IPF临床试验的事后分析,比较吡非尼酮与安慰剂对呼吸困难严重程度的影响。

主要发现

  • 吡非尼酮可能延缓疾病更晚期患者报告的呼吸困难在12个月内的恶化。
  • 既往汇总分析提示,较严重患者呼吸困难恶化更常见,且可能从吡非尼酮对呼吸困难分类恶化或死亡的获益更大。

临床怎么用

  • 对于疾病更晚期(GAP II/III期或FVC<80%)的IPF患者,可考虑使用吡非尼酮以延缓呼吸困难恶化。

局限性

  • 该结果为事后分析,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

New post hoc analysis of IPF clinical trials suggests that treatment with pirfenidone slows the worsening of patient-reported breathlessness over 12 months versus placebo in patients with more advanced disease (GAP stage II/III or FVC <80%) http://bit.ly/2yJyUVT Dyspnoea is a frequent and debilitating symptom in patients with idiopathic pulmonary fibrosis (IPF) and is reported as the most important factor determining their health-related quality of life (QoL) [1–3]. Previous post hoc analysis of pooled data from IPF clinical trials has shown that a worsening of dyspnoea was particularly likely in patients with more severe versus less severe disease [4]. Interestingly, it has been suggested that patients with more severe disease may experience a greater benefit from pirfenidone on categorical worsening of dyspnoea or death compared with patients with less severe disease [4]. Here, we report the results of a post hoc analysis aiming to further examine the effect of pirfenidone compared with placebo on dyspnoea severity in patients with IPF, including the change from baseline in dyspnoea over 12 months and categorical changes in dyspnoea at 12 months.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Glassberg MK, Wijsenbeek MS, Gilberg F, et al. Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019. PMID: 31164431. doi:10.1183/13993003.00399-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。